Preparatory studies for possible HIV vaccine trials in northern Thailand.

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Preparatory studies for possible HIV vaccine trials in northern Thailand.

AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S243-6. Unique Identifier : AIDSLINE MED/95169492
Nelson KE; Beyrer C; Natpratan C; Eiumtrakul S; Celentano DD; Khamboonruang C; Department of Epidemiology, Johns Hopkins University, School of; Hygiene and Public Health, Baltimore, Maryland.

Abstract: We studied several populations of human immunodeficiency virus (HIV)-seronegative individuals from northern Thailand who were believed to be at relatively high risk of HIV infection in order to assess their potential suitability for inclusion in a preventive HIV vaccine trial. Included were female commercial sex workers (CSWs), male sexually transmitted disease (STD) clinic patients, male conscripts into the Royal Thai Army (RTA), and men who were recently discharged from the army. We evaluated their HIV prevalence, their interest in study participation, their compliance with prospective follow-up, and their HIV incidence. Among 1068 female CSWs the baseline HIV prevalence was 38.3%; of 659 HIV seronegatives 395 (59.9%) agreed to enrollment in the study. Follow-up at 6-9 months was 73.2%; it was 58% in brothel-based CSWs and 85% in non-brothel-based CSWs. Overall HIV incidence in CSWs was 8.2 per 100 person-years; incidence was 29 per 100 person-years in brothel-based CSWs and 4 per 100 person-years in non-brothel-based CSWs. Among 1031 male STD clinic patients, baseline HIV prevalence was 15.9%, follow-up was successful in 98.1%, and HIV incidence was 4.0 per 100 person-years. Among four cohorts of RTA conscripts who entered the military in 1991 and 1993, baseline HIV prevalence has been about 12%, follow-up about 90%, and HIV incidence has varied from 1.2-3.2 per 100 person-years. Discharged RTA conscripts have had baseline HIV prevalence of about 13%, successful follow-up of 94%, and an HIV incidence of about 5 per 100 person-years.(ABSTRACT TRUNCATED AT 250 WORDS)

Keywords: Adult AIDS Vaccines/*PHARMACOLOGY Clinical Trials/*METHODS Female Human HIV Infections/COMPLICATIONS/PREVENTION & CONTROL HIV Seronegativity HIV Seroprevalence Male Military Personnel Patient Selection Prospective Studies Prostitution Risk Factors Sexually Transmitted Diseases/COMPLICATIONS Support, U.S. Gov't, P.H.S. Thailand/EPIDEMIOLOGY JOURNAL ARTICLE
950630
M9561124

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .